Annual EBITDA
-$37.75 M
+$35.72 M+48.62%
31 December 2023
Summary:
Seelos Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$37.75 million, with the most recent change of +$35.72 million (+48.62%) on 31 December 2023. During the last 3 years, it has risen by +$26.70 million (+41.43%). SEEL annual EBITDA is now -723.94% below its all-time high of $6.05 million, reached on 31 December 1998.SEEL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$1.75 M
+$4.37 M+166.57%
30 June 2024
Summary:
Seelos Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently $1.75 million, with the most recent change of +$4.37 million (+166.57%) on 30 June 2024. Over the past year, it has increased by +$7.17 million (+132.26%). SEEL quarterly EBITDA is now -83.44% below its all-time high of $10.55 million, reached on 30 September 2023.SEEL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$4.26 M
+$31.22 M+115.79%
30 June 2024
Summary:
Seelos Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $4.26 million, with the most recent change of +$31.22 million (+115.79%) on 30 June 2024. Over the past year, it has increased by +$42.01 million (+111.28%). SEEL TTM EBITDA is now at all-time high.SEEL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SEEL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +132.3% | +111.3% |
| 3 y3 years | +41.4% | +106.4% | +106.6% |
| 5 y5 years | +26.3% | +116.4% | +108.3% |
SEEL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +48.6% | -83.4% | +105.9% | at high | +105.2% |
| 5 y | 5 years | -99.3% | +48.6% | -83.4% | +105.9% | at high | +105.2% |
| alltime | all time | -723.9% | +48.6% | -83.4% | +104.9% | at high | +105.2% |
Seelos Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $1.75 M(-166.6%) | $4.26 M(-115.8%) |
| Mar 2024 | - | -$2.63 M(-51.5%) | -$26.97 M(-28.6%) |
| Dec 2023 | -$37.75 M(-48.6%) | -$5.42 M(-151.3%) | -$37.75 M(-25.9%) |
| Sept 2023 | - | $10.55 M(-135.8%) | -$50.94 M(-37.2%) |
| June 2023 | - | -$29.48 M(+119.8%) | -$81.09 M(+11.3%) |
| Mar 2023 | - | -$13.41 M(-27.9%) | -$72.88 M(-0.8%) |
| Dec 2022 | -$73.47 M(+14.0%) | -$18.60 M(-5.1%) | -$73.47 M(-10.5%) |
| Sept 2022 | - | -$19.60 M(-7.8%) | -$82.12 M(+12.0%) |
| June 2022 | - | -$21.27 M(+52.0%) | -$73.31 M(+21.5%) |
| Mar 2022 | - | -$13.99 M(-48.7%) | -$60.32 M(-6.4%) |
| Dec 2021 | -$64.45 M(+240.3%) | -$27.25 M(+152.5%) | -$64.45 M(+48.2%) |
| Sept 2021 | - | -$10.79 M(+30.5%) | -$43.49 M(+18.2%) |
| June 2021 | - | -$8.28 M(-54.3%) | -$36.78 M(+14.1%) |
| Mar 2021 | - | -$18.13 M(+187.8%) | -$32.23 M(+70.2%) |
| Dec 2020 | -$18.94 M(-63.0%) | -$6.30 M(+54.2%) | -$18.94 M(-18.7%) |
| Sept 2020 | - | -$4.08 M(+9.6%) | -$23.30 M(+3.9%) |
| June 2020 | - | -$3.73 M(-22.8%) | -$22.43 M(+9.1%) |
| Mar 2020 | - | -$4.83 M(-54.7%) | -$20.56 M(-59.9%) |
| Dec 2019 | -$51.23 M(+458.2%) | -$10.66 M(+231.0%) | -$51.23 M(+7.5%) |
| Sept 2019 | - | -$3.22 M(+73.9%) | -$47.64 M(+4.8%) |
| June 2019 | - | -$1.85 M(-94.8%) | -$45.45 M(-0.8%) |
| Mar 2019 | - | -$35.50 M(+401.6%) | -$45.83 M(+264.0%) |
| Dec 2018 | -$9.18 M(-20.5%) | -$7.08 M(+587.0%) | -$12.59 M(+55.4%) |
| Sept 2018 | - | -$1.03 M(-53.7%) | -$8.10 M(-26.8%) |
| June 2018 | - | -$2.23 M(-1.4%) | -$11.06 M(+5.0%) |
| Mar 2018 | - | -$2.26 M(-12.7%) | -$10.54 M(-8.6%) |
| Dec 2017 | -$11.55 M(+75.8%) | -$2.59 M(-35.2%) | -$11.53 M(+27.4%) |
| Sept 2017 | - | -$3.99 M(+134.2%) | -$9.05 M(+42.5%) |
| June 2017 | - | -$1.70 M(-47.6%) | -$6.35 M(-16.1%) |
| Mar 2017 | - | -$3.25 M(+3058.3%) | -$7.57 M(+16.8%) |
| Dec 2016 | -$6.57 M(-63.1%) | -$103.00 K(-92.0%) | -$6.48 M(-22.2%) |
| Sept 2016 | - | -$1.29 M(-55.9%) | -$8.33 M(-29.0%) |
| June 2016 | - | -$2.92 M(+35.1%) | -$11.73 M(-15.0%) |
| Mar 2016 | - | -$2.16 M(+10.6%) | -$13.81 M(-22.5%) |
| Dec 2015 | -$17.83 M(-18.8%) | -$1.96 M(-58.3%) | -$17.83 M(-45.9%) |
| Sept 2015 | - | -$4.69 M(-6.2%) | -$32.97 M(+5.3%) |
| June 2015 | - | -$5.00 M(-19.1%) | -$31.31 M(+25.2%) |
| Mar 2015 | - | -$6.18 M(-63.9%) | -$25.01 M(+13.9%) |
| Dec 2014 | -$21.97 M(+45.8%) | -$17.10 M(+465.1%) | -$21.97 M(+244.7%) |
| Sept 2014 | - | -$3.03 M(-333.8%) | -$6.37 M(+0.3%) |
| June 2014 | - | $1.29 M(-141.3%) | -$6.36 M(-44.7%) |
| Mar 2014 | - | -$3.13 M(+108.2%) | -$11.50 M(-23.6%) |
| Dec 2013 | -$15.07 M(-38.8%) | -$1.51 M(-50.0%) | -$15.07 M(-46.8%) |
| Sept 2013 | - | -$3.01 M(-21.9%) | -$28.31 M(+4.1%) |
| June 2013 | - | -$3.85 M(-42.5%) | -$27.19 M(-1.1%) |
| Mar 2013 | - | -$6.70 M(-54.6%) | -$27.49 M(+13.2%) |
| Dec 2012 | -$24.63 M(+42.7%) | -$14.75 M(+677.8%) | -$24.29 M(+75.6%) |
| Sept 2012 | - | -$1.90 M(-54.3%) | -$13.83 M(-1.7%) |
| June 2012 | - | -$4.15 M(+18.7%) | -$14.07 M(-19.9%) |
| Mar 2012 | - | -$3.50 M(-18.4%) | -$17.58 M(+1.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$17.26 M(-12.4%) | -$4.29 M(+100.6%) | -$17.26 M(-33.2%) |
| Sept 2011 | - | -$2.14 M(-72.1%) | -$25.84 M(-0.7%) |
| June 2011 | - | -$7.66 M(+140.9%) | -$26.01 M(+25.0%) |
| Mar 2011 | - | -$3.18 M(-75.3%) | -$20.80 M(+6.0%) |
| Dec 2010 | -$19.70 M(+479.9%) | -$12.86 M(+457.1%) | -$19.63 M(+118.2%) |
| Sept 2010 | - | -$2.31 M(-5.7%) | -$9.00 M(+19.7%) |
| June 2010 | - | -$2.45 M(+22.2%) | -$7.52 M(+19.6%) |
| Mar 2010 | - | -$2.01 M(-10.2%) | -$6.28 M(+85.0%) |
| Dec 2009 | -$3.40 M(-26.4%) | -$2.23 M(+169.0%) | -$3.40 M(+429.9%) |
| Sept 2009 | - | -$830.10 K(-31.7%) | -$641.00 K(-75.2%) |
| June 2009 | - | -$1.22 M(-237.8%) | -$2.59 M(+10.6%) |
| Mar 2009 | - | $882.10 K(+68.8%) | -$2.34 M(-49.3%) |
| Dec 2008 | -$4.62 M(-44.8%) | $522.70 K(-118.8%) | -$4.62 M(-42.1%) |
| Sept 2008 | - | -$2.78 M(+186.6%) | -$7.98 M(+13.0%) |
| June 2008 | - | -$968.40 K(-30.5%) | -$7.06 M(-10.6%) |
| Mar 2008 | - | -$1.39 M(-50.9%) | -$7.90 M(-5.5%) |
| Dec 2007 | -$8.36 M(+5.0%) | -$2.84 M(+52.5%) | -$8.36 M(+9.2%) |
| Sept 2007 | - | -$1.86 M(+3.1%) | -$7.65 M(+1.4%) |
| June 2007 | - | -$1.81 M(-2.5%) | -$7.55 M(+5.5%) |
| Mar 2007 | - | -$1.85 M(-13.2%) | -$7.16 M(-10.1%) |
| Dec 2006 | -$7.96 M(-44.9%) | -$2.13 M(+21.3%) | -$7.96 M(-11.0%) |
| Sept 2006 | - | -$1.76 M(+24.4%) | -$8.95 M(-11.3%) |
| June 2006 | - | -$1.41 M(-46.7%) | -$10.09 M(-20.9%) |
| Mar 2006 | - | -$2.65 M(-15.1%) | -$12.76 M(-11.6%) |
| Dec 2005 | -$14.43 M(-11.5%) | -$3.12 M(+7.8%) | -$14.43 M(-8.7%) |
| Sept 2005 | - | -$2.90 M(-29.1%) | -$15.80 M(-8.6%) |
| June 2005 | - | -$4.09 M(-5.6%) | -$17.30 M(+1.7%) |
| Mar 2005 | - | -$4.33 M(-3.7%) | -$17.01 M(+4.3%) |
| Dec 2004 | -$16.31 M(+25.7%) | -$4.49 M(+2.3%) | -$16.31 M(-0.4%) |
| Sept 2004 | - | -$4.39 M(+15.4%) | -$16.37 M(+12.8%) |
| June 2004 | - | -$3.80 M(+5.0%) | -$14.51 M(+5.0%) |
| Mar 2004 | - | -$3.62 M(-20.5%) | -$13.81 M(+103.1%) |
| Dec 2003 | -$12.98 M(-51.0%) | -$4.56 M(+80.4%) | -$6.80 M(-32.9%) |
| Sept 2003 | - | -$2.53 M(-18.6%) | -$10.13 M(-27.8%) |
| June 2003 | - | -$3.11 M(-191.6%) | -$14.02 M(-20.5%) |
| Mar 2003 | - | $3.39 M(-143.0%) | -$17.63 M(-33.4%) |
| Dec 2002 | -$26.49 M(+58.9%) | -$7.89 M(+22.9%) | -$26.49 M(+8.0%) |
| Sept 2002 | - | -$6.42 M(-4.4%) | -$24.53 M(+13.3%) |
| June 2002 | - | -$6.71 M(+22.8%) | -$21.65 M(+16.2%) |
| Mar 2002 | - | -$5.47 M(-7.6%) | -$18.63 M(+11.7%) |
| Dec 2001 | -$16.68 M(+69.4%) | -$5.92 M(+67.2%) | -$16.68 M(+15.7%) |
| Sept 2001 | - | -$3.54 M(-4.2%) | -$14.41 M(+10.0%) |
| June 2001 | - | -$3.70 M(+5.3%) | -$13.10 M(+9.4%) |
| Mar 2001 | - | -$3.51 M(-4.0%) | -$11.98 M(+21.7%) |
| Dec 2000 | -$9.84 M(+145.9%) | -$3.66 M(+64.1%) | -$9.84 M(+59.2%) |
| Sept 2000 | - | -$2.23 M(-13.4%) | -$6.18 M(+56.4%) |
| June 2000 | - | -$2.58 M(+86.7%) | -$3.95 M(+186.7%) |
| Mar 2000 | - | -$1.38 M | -$1.38 M |
| Dec 1999 | -$4.00 M(-166.2%) | - | - |
| Dec 1998 | $6.05 M(-258.6%) | - | - |
| Dec 1997 | -$3.82 M | - | - |
FAQ
- What is Seelos Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly EBITDA year-on-year change?
- What is Seelos Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Seelos Therapeutics?
- What is Seelos Therapeutics TTM EBITDA year-on-year change?
What is Seelos Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SEEL is -$37.75 M
What is the all time high annual EBITDA for Seelos Therapeutics?
Seelos Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $6.05 M
What is Seelos Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SEEL is $1.75 M
What is the all time high quarterly EBITDA for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $10.55 M
What is Seelos Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SEEL quarterly earnings before interest, taxes, depreciation & amortization has changed by +$7.17 M (+132.26%)
What is Seelos Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SEEL is $4.26 M
What is the all time high TTM EBITDA for Seelos Therapeutics?
Seelos Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $4.26 M
What is Seelos Therapeutics TTM EBITDA year-on-year change?
Over the past year, SEEL TTM earnings before interest, taxes, depreciation & amortization has changed by +$42.01 M (+111.28%)